

Jan Weber received his Ph.D. in 2001 from the Academy of Sciences of the Czech Republic. Following a six-year postdoctoral stay at the Cleveland Clinic in Ohio and five years in research and development at a diagnostic company, he returned to the Czech Republic, where he currently heads the Virology Group at the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences in Prague. His current research focuses on the identification of novel antiviral drug targets, the discovery of new antiviral compounds, and the development of antiviral nanoparticles against various viruses, including influenza viruses, SARS-CoV-2, and MPXV. His other research interests include the interaction of the hepatitis B virus core protein with host-cell proteins, novel strategies for HIV inhibition, and innovative approaches to targeting viral attachment and entry into host cells.